---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-116657"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:59:43.884149+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Leap Therapeutics Q3 net loss $13.7M; DKN-01 colorectal study expands to Part B

## Summary
- Net loss $13.7M in Q3 2023 vs $15.1M in Q3 2022; cash and equivalents $80.7M.
- DKN-01 DeFianCe Part A met >20% ORR threshold; Part B with 130 patients now enrolling; data at Jan 2024 med conf.
- DisTinGuish gastric cancer Part C enrollment expected by end 2023; prior data showed 73% ORR, 19.5 mo OS.
- R&D expenses $11.5M vs $12.1M; G&A $3.3M vs $3.2M.

## SEC filing metadata
- accession: 0001104659-23-116657
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465923116657/0001104659-23-116657-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465923116657/tm2330433d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-116657
- JSON: https://secwatch.observer/filing/0001104659-23-116657.json
- Plain text: https://secwatch.observer/filing/0001104659-23-116657.txt

## Key facts
- Earnings Releases
  CYPHERPUNK TECHNOLOGIES INC. reported the third quarter ended September 30, 2023 results: net income Net Loss was $13.7 million.
  - Period: the third quarter ended September 30, 2023
  - Net income: Net Loss was $13.7 million
  - Result: reported results
  source text: Net Loss was $13.7 million for the third quarter 2023, compared to $15.1 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1509745/000110465923116657/0001104659-23-116657-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.